Background: Lung is often affected by metastases from other organs that are subject of surgery. The efficacy of surgical treatment in pulmonary metastases depends on type of primary tumors and several clinical factors such as: risk of metastasis in other organs, sensitivity to chemotherapy and hormonotherapy and the possibility of a new primary tumor. The aim of our study was to find the most common metastasis in lung, to evaluate the benefits of metastasectomy and the possible prognostic factors associated with overall survival after surgical treatment. Methods: This is a retrospective, descriptive study from January 2004 to December 2014. Data were examined for age, gender, primary tumor histology, operative approaches and resection margins. The surgical approach used was wedge resection in free margins confirmed also by histopathology. Kaplan-Meier analysis was used to estimate the survival data one year after metastasectomy. Results: 112 pulmonary metastasectomies were performed (males 64, females 48). Median age was 38.2 years. Definitive pathology revealed sarcoma in 54%, epithelial tumor in 36%, and melanoma in 10%. Complete resection (R0) was achieved in all patients. Average postoperative hospital length of stay was 7.4 days. The 1-year survival rates were 64% for epithelial tumors, 43% for sarcomas. Conclusions: Most common lung metastasis was sarcoma but epithelial tumor profits much more from metastasectomy. Pulmonary metastasectomy is an effective choice of treatment. Univariate analyses verified that histopathology of the tumor, disease-free interval, number of metastatic lesions, and lymph node involvement were significant prognostic factors in patients undergoing pulmonary metastasectomy. Legal entity responsible for the study:

No abstract

No abstract

AECOPD have major implications on the quality of life, morbidity and mortality of COPD patients. In addition to their assessment on clinical presentation, which can be variable and difficult to predict, a large number of biomarkers are used. Inflammation increases during exacerbations of COPD and there are changes in systemic markers like CRP, IL 6 and PARC/CC18, as well as the cell structure in sputum and blood. The aim of this study was to investigate the diagnostic and prognostic value of plasma biomarkers levels, sputum and hematic cell profile in patients with AECOPD. Mean concentration of serum markers studied were higher in first consultation, and significantly decreasing 21 days after. The number of cells in sputum and their structure, number of blood leucocytes has significant differences with results after 21 days. NLR resulted a reliable indicator and simple in the determining of inflammation growth. Diagnosis of AECOPD is supported by increased sputum inflammation and increased systemic inflammation as demonstrated by increased number of blood cells. IL-6, PARC/CCL-18, and CRP resulted useful for diagnosis of AECOPD and to followup stabilization. AECOPD inflammation is more evident in stage IV of the diseases.

No abstract